An investigational oral drug called ONO-4641 reduced the number of lesions in people with multiple sclerosis, according to the results of a phase two clinical trial.
An investigational oral drug called ONO-4641 reduced the number of lesions in people with multiple sclerosis, according to the results of a phase two clinical trial.